Related Experiment Video

Updated: May 16, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Select-agent status could slow development of anti-SARS therapies

Susan Matthews

    Nature Medicine
    |December 11, 2012
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
    05:46

    Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

    Published on: April 9, 2014

    Engineering Antiviral Agents via Surface Plasmon Resonance
    13:00

    Engineering Antiviral Agents via Surface Plasmon Resonance

    Published on: June 14, 2022

    Related Experiment Videos

    Last Updated: May 16, 2026

    Assay Development for High-Throughput Drug Screening Against Mycobacteria
    07:50

    Assay Development for High-Throughput Drug Screening Against Mycobacteria

    Published on: October 25, 2024

    Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
    05:46

    Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

    Published on: April 9, 2014

    Engineering Antiviral Agents via Surface Plasmon Resonance
    13:00

    Engineering Antiviral Agents via Surface Plasmon Resonance

    Published on: June 14, 2022

    Related Concept Videos

    Structure-Activity Relationships and Drug Design01:28

    Structure-Activity Relationships and Drug Design

    Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
    SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
    Preclinical Development: Overview01:28

    Preclinical Development: Overview

    Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

    Articles linked to this work by shared authors, journal, and citation graph.

    Impact of decentralised, community-led molecular STI point-of-care testing on testing practices in remote First Nations communities in Australia.

    Sexually transmitted infections·2026

    Reference intervals for haptoglobin in neonates and children 30 days to 18 years old.

    Scandinavian journal of clinical and laboratory investigation·2026

    Policymaker Perspectives on the Role of Health Systems in Sustainable Hepatitis C Point-Of-Care Testing in Australia.

    Journal of viral hepatitis·2025

    "It's not just running the test": Operator experiences of implementing a decentralised hepatitis C point-of-care testing program in Australia.

    The International journal on drug policy·2025

    Clinical effectiveness and analytical quality of a national point-of-care testing network for sexually transmitted infections integrated into rural and remote primary care clinics in Australia, 2016-2022: an observational program evaluation.

    The Lancet regional health. Western Pacific·2024

    Independent clinic-based evaluation of point-of-care testing for the screening of Chlamydia trachomatis, Neisseria gonorrhoea and Trichomonas vaginalis in women-at-risk in Australia, Guatemala, Morocco, and South Africa.

    BMC infectious diseases·2024

    Emergence and spread of Plasmodium falciparum PX1 polymorphisms associated with decreased susceptibility to antimalarials in Uganda.

    Nature medicine·2026

    Histological aging signatures for monitoring tissue-specific aging and disease.

    Nature medicine·2026

    How to build an AI-driven digital organism.

    Nature medicine·2026

    First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial.

    Nature medicine·2026

    Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.

    Nature medicine·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us